|Dupilumab was originally evaluated as a treatment for atopic allergic conditions, including asthma , atopic dermatitis (AD) and nasal polyposis . A list of trials registered at ClinicalTrials.gov is available here.
The first full regulatory approval for dupilumab was granted by the FDA in March 2017 and this was for the treatment of moderate-to-severe eczema (atopic dermatitis). The EMA granted this same approval in August 2017. In October 2018, FDA approval was expanded to encompass the treatment of patients with eosinophilic type or oral corticosteroid-dependent moderate-to-severe asthma. June 2019 saw FDA approval expanded to include treatment of patients with uncontrolled chronic rhinosinusitis with nasal polyposis.